

Benign Prostatic Hyperplasia (BPH) Drugs-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/BA8EDDFEE8BMEN.html>

Date: May 2018

Pages: 157

Price: US\$ 3,480.00 (Single User License)

ID: BA8EDDFEE8BMEN

Abstracts

Report Summary

Benign Prostatic Hyperplasia (BPH) Drugs-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Benign Prostatic Hyperplasia (BPH) Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Benign Prostatic Hyperplasia (BPH) Drugs 2013-2017, and development forecast 2018-2023

Main market players of Benign Prostatic Hyperplasia (BPH) Drugs in EMEA, with company and product introduction, position in the Benign Prostatic Hyperplasia (BPH) Drugs market

Market status and development trend of Benign Prostatic Hyperplasia (BPH) Drugs by types and applications

Cost and profit status of Benign Prostatic Hyperplasia (BPH) Drugs, and marketing status

Market growth drivers and challenges

The report segments the EMEA Benign Prostatic Hyperplasia (BPH) Drugs market as:

EMEA Benign Prostatic Hyperplasia (BPH) Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe
Middle East
Africa

EMEA Benign Prostatic Hyperplasia (BPH) Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Alpha-blocker
Phosphodiesterase Type-5 Inhibitors
5-alpha-Reductase Inhibitors

EMEA Benign Prostatic Hyperplasia (BPH) Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospitals
Clinics
Others

EMEA Benign Prostatic Hyperplasia (BPH) Drugs Market: Players Segment Analysis (Company and Product introduction, Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Revenue, Price and Gross Margin):

Astellas Pharma
Eli Lilly
GlaxoSmithKline
Sanofi
ADC Therapeutics
Bayer HealthCare
Bristol-Myers Squibb
Valeant Pharmaceuticals
Endo Pharmaceuticals
Foresee Pharmaceuticals
Madrigal Pharmaceuticals
Merck
Novartis
Spectrum Pharmaceuticals
Takeda Pharmaceuticals

Teva

Advaxis

ANI Pharmaceuticals

BHR Pharma

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS

- 1.1 Definition of Benign Prostatic Hyperplasia (BPH) Drugs in This Report
- 1.2 Commercial Types of Benign Prostatic Hyperplasia (BPH) Drugs
 - 1.2.1 Alpha-blocker
 - 1.2.2 Phosphodiesterase Type-5 Inhibitors
 - 1.2.3 5-alpha-Reductase Inhibitors
- 1.3 Downstream Application of Benign Prostatic Hyperplasia (BPH) Drugs
 - 1.3.1 Hospitals
 - 1.3.2 Clinics
 - 1.3.3 Others
- 1.4 Development History of Benign Prostatic Hyperplasia (BPH) Drugs
- 1.5 Market Status and Trend of Benign Prostatic Hyperplasia (BPH) Drugs 2013-2023
 - 1.5.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Benign Prostatic Hyperplasia (BPH) Drugs Market Status and Trend 2013-2023

CHAPTER 2 ASIA PACIFIC MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Benign Prostatic Hyperplasia (BPH) Drugs in Asia Pacific 2013-2017
- 2.2 Consumption Market of Benign Prostatic Hyperplasia (BPH) Drugs in Asia Pacific by Regions
 - 2.2.1 Consumption Volume of Benign Prostatic Hyperplasia (BPH) Drugs in Asia Pacific by Regions
 - 2.2.2 Revenue of Benign Prostatic Hyperplasia (BPH) Drugs in Asia Pacific by Regions
- 2.3 Market Analysis of Benign Prostatic Hyperplasia (BPH) Drugs in Asia Pacific by Regions
 - 2.3.1 Market Analysis of Benign Prostatic Hyperplasia (BPH) Drugs in China 2013-2017
 - 2.3.2 Market Analysis of Benign Prostatic Hyperplasia (BPH) Drugs in Japan 2013-2017
 - 2.3.3 Market Analysis of Benign Prostatic Hyperplasia (BPH) Drugs in Korea 2013-2017
 - 2.3.4 Market Analysis of Benign Prostatic Hyperplasia (BPH) Drugs in India 2013-2017

2.3.5 Market Analysis of Benign Prostatic Hyperplasia (BPH) Drugs in Southeast Asia 2013-2017

2.3.6 Market Analysis of Benign Prostatic Hyperplasia (BPH) Drugs in Australia 2013-2017

2.4 Market Development Forecast of Benign Prostatic Hyperplasia (BPH) Drugs in Asia Pacific 2018-2023

2.4.1 Market Development Forecast of Benign Prostatic Hyperplasia (BPH) Drugs in Asia Pacific 2018-2023

2.4.2 Market Development Forecast of Benign Prostatic Hyperplasia (BPH) Drugs by Regions 2018-2023

CHAPTER 3 ASIA PACIFIC MARKET STATUS AND FORECAST BY TYPES

3.1 Whole Asia Pacific Market Status by Types

3.1.1 Consumption Volume of Benign Prostatic Hyperplasia (BPH) Drugs in Asia Pacific by Types

3.1.2 Revenue of Benign Prostatic Hyperplasia (BPH) Drugs in Asia Pacific by Types

3.2 Asia Pacific Market Status by Types in Major Countries

3.2.1 Market Status by Types in China

3.2.2 Market Status by Types in Japan

3.2.3 Market Status by Types in Korea

3.2.4 Market Status by Types in India

3.2.5 Market Status by Types in Southeast Asia

3.2.6 Market Status by Types in Australia

3.3 Market Forecast of Benign Prostatic Hyperplasia (BPH) Drugs in Asia Pacific by Types

CHAPTER 4 ASIA PACIFIC MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Benign Prostatic Hyperplasia (BPH) Drugs in Asia Pacific by Downstream Industry

4.2 Demand Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Downstream Industry in Major Countries

4.2.1 Demand Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Downstream Industry in China

4.2.2 Demand Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Downstream Industry in Japan

4.2.3 Demand Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Downstream

Industry in Korea

4.2.4 Demand Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Downstream

Industry in India

4.2.5 Demand Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Downstream

Industry in Southeast Asia

4.2.6 Demand Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Downstream
Industry in Australia

4.3 Market Forecast of Benign Prostatic Hyperplasia (BPH) Drugs in Asia Pacific by
Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS

5.1 Asia Pacific Economy Situation and Trend Overview

5.2 Benign Prostatic Hyperplasia (BPH) Drugs Downstream Industry Situation and
Trend Overview

CHAPTER 6 BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN ASIA PACIFIC

6.1 Sales Volume of Benign Prostatic Hyperplasia (BPH) Drugs in Asia Pacific by Major
Players

6.2 Revenue of Benign Prostatic Hyperplasia (BPH) Drugs in Asia Pacific by Major
Players

6.3 Basic Information of Benign Prostatic Hyperplasia (BPH) Drugs by Major Players

6.3.1 Headquarters Location and Established Time of Benign Prostatic Hyperplasia
(BPH) Drugs Major Players

6.3.2 Employees and Revenue Level of Benign Prostatic Hyperplasia (BPH) Drugs
Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Astellas Pharma

7.1.1 Company profile

- 7.1.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
- 7.1.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Astellas Pharma
- 7.2 Eli Lilly
 - 7.2.1 Company profile
 - 7.2.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.2.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly
- 7.3 GlaxoSmithKline
 - 7.3.1 Company profile
 - 7.3.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.3.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
- 7.4 Sanofi
 - 7.4.1 Company profile
 - 7.4.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.4.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Sanofi
- 7.5 ADC Therapeutics
 - 7.5.1 Company profile
 - 7.5.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.5.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of ADC Therapeutics
- 7.6 Bayer HealthCare
 - 7.6.1 Company profile
 - 7.6.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.6.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Bayer HealthCare
- 7.7 Bristol-Myers Squibb
 - 7.7.1 Company profile
 - 7.7.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.7.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
- 7.8 Valeant Pharmaceuticals
 - 7.8.1 Company profile
 - 7.8.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.8.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Valeant Pharmaceuticals
- 7.9 Endo Pharmaceuticals

- 7.9.1 Company profile
- 7.9.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
- 7.9.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Endo Pharmaceuticals
- 7.10 Foresee Pharmaceuticals
 - 7.10.1 Company profile
 - 7.10.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.10.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Foresee Pharmaceuticals
- 7.11 Madrigal Pharmaceuticals
 - 7.11.1 Company profile
 - 7.11.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.11.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Madrigal Pharmaceuticals
- 7.12 Merck
 - 7.12.1 Company profile
 - 7.12.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.12.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Merck
- 7.13 Novartis
 - 7.13.1 Company profile
 - 7.13.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.13.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Novartis
- 7.14 Spectrum Pharmaceuticals
 - 7.14.1 Company profile
 - 7.14.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.14.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Spectrum Pharmaceuticals
- 7.15 Takeda Pharmaceuticals
 - 7.15.1 Company profile
 - 7.15.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product
 - 7.15.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Takeda Pharmaceuticals
- 7.16 Teva
- 7.17 Advaxis
- 7.18 ANI Pharmaceuticals
- 7.19 BHR Pharma

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS

- 8.1 Industry Chain of Benign Prostatic Hyperplasia (BPH) Drugs
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS

- 9.1 Cost Structure Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
- 9.2 Raw Materials Cost Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
- 9.3 Labor Cost Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
- 9.4 Manufacturing Expenses Analysis of Benign Prostatic Hyperplasia (BPH) Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: Benign Prostatic Hyperplasia (BPH) Drugs-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/BA8EDDFEE8BMEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BA8EDDFEE8BMEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

